HealthProtocols
← All sources

N=1 Reports on rapamycin.news

N=1 data from 3 participant(s). Tomnook (age 69M): −15% HRV / +2–3 bpm; Texasgirl: −6–8 ms HRV / +7–8 bpm RHR per cycle; Newbalance: Cyclical HRV suppression correlated with carb load; independ

N=1 Self-Experiment Data

Tomnook (age 69M)

  • Protocol: Rapamycin 1mg escalating to 6mg over 5 weeks + indoor rowing 20 min/day
  • Before: HRV 20–40 ms; occasional spikes >100 ms
  • After: HRV −15% overall; RHR +2–3 bpm; BP 115/73 → 120/75
  • Change: −15% HRV / +2–3 bpm
  • Duration: 5 wks
  • Device: Apple Watch + Oura + 24h BP + CGM

Texasgirl

  • Protocol: Rapamycin 2mg + GFJ weekly (or 4mg + GFJ biweekly). Uses wearable to time next dose
  • Before: Baseline: RHR high 50s / HRV 20 ms
  • After: Post-dose: RHR mid 60s / HRV 12–14 ms; returns to baseline within days
  • Change: −6–8 ms HRV / +7–8 bpm RHR per cycle
  • Duration: Ongoing; dozens of cycles
  • Device: Oura Ring

Newbalance

  • Protocol: High-glycemic foods at night consistently tracked — compared before/after starting rapamycin to rule it out as variable
  • Before: Baseline (normal evenings)
  • After: Lower overnight HRV on high-glycemic evenings
  • Change: Cyclical HRV suppression correlated with carb load; independent of rapamycin
  • Duration: Ongoing observation
  • Device: Oura Ring + HRV4Training

Outcomes

  • Heart Rate Variability
    20
    ms (RMSSD)
  • Resting Heart Rate
    3
    bpm (Beats Per Minute)
  • Heart Rate Variability
    15
    ms (RMSSD)
  • Heart Rate Variability
    12
    ms (RMSSD)
  • Heart Rate Variability
    7
    ms (RMSSD)
  • Resting Heart Rate
    8
    bpm (Beats Per Minute)
View original paper →